Study of Risk Factors and Clinical Characterization of Rapidly Growing Melanoma

NCT02879474 | Unknown

• 2 other identifiers: AORC 2009RC13_0082
• Study Type: observational
• Target: 472
• Locations: 1 country
• Sites: 1

Brief Summary

State of the question Over the past decade, the incidence of melanoma (MM) has steadily increased in France and in most developed countries. This increased incidence was concerned mainly MM thin while the incidence of MM thick that represent the true "killers", and mortality from MM remained stable or increased slightly over the same period. These epidemiological data and observations from everyday medical practice dermatologists suggest the existence of different growth patterns within MM. Indeed, some MM progressing slowly sometimes for decades before diagnosis but are thin at the time of resection. Conversely, others MM grow very quickly, resulting in thick tumors despite a diagnosis and resection sometimes very early. These fast growing MM (FGMM) probably contribute significantly to the relative mortality in MM, as improved screening failed to influence to this day. Our team has already demonstrated that the growth kinetics of the MM was a prognostic factor of tumor aggressiveness regardless of the thickness of the tumor. Using the same method to calculate the growth rate, an Australian team recently studied the growth rate in a population of patients suffering from MM. In this population 1/3 of MM had a growth of more than 0.5 mm per month. Clinical aspects and FGMM of these risk factors were individuals (injuries symmetrical achromic and regular occurrence among about older and low-nevi). The European and Australian people are very different in particular regarding the prevention policy, these results can not be extrapolated to the French population.The main objective is to identify risk factors for FGMM in French propulation

Conditions

Melanoma Cancer

Outcome Measures

Primary Outcomes (1)

• Speed growth of melanoma size

  1 year

Study Arms (1)

Patient with melanoma

Behavioral: Melanoma scale questionnair

Interventions

Melanoma scale questionnair BEHAVIORAL

Patient with melanoma

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Breslow primitive melanoma \>1 mm patients

You may qualify if:

• Patient with Breslow primitive melanoma for over 1 mm skin affected

You may not qualify if:

• Patient unable to answer questionnair concerning its melanoma history desease

Sponsors & Collaborators

• Assistance Publique Hopitaux De Marseille: lead

Study Sites (1)

Assistance Publique Hopitaux de Marseille

Marseille, 13354, France

Location

Study Officials

• Urielle DESALBRES

  Assistance Publique Hopitaux De Marseille

  STUDY DIRECTOR

• Caroline GAUDY, MD/PhD

  Assistance Publique Hopitaux De Marseille

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 22, 2016
• First Posted: August 25, 2016
• Study Start: August 1, 2010
• Primary Completion: May 1, 2016
• Study Completion: May 1, 2017
• Last Updated: August 25, 2016

Record last verified: 2016-08

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)